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PreviewsTumor cells are relentless oppor-
tunists, willing to take advantage of 
every imaginable means to sustain 
their survival. The NF-κB signaling 
pathway is chronically active in a 
variety of tumor cell types, and this 
sustained activity leads to the patho-
logical expression of NF-κB target 
genes, including ones involved in cell 
proliferation, cell survival, cell adhe-
sion, and inflammation.
Multiple myeloma (MM) is a rela-
tively common, progressive 
hematological malignancy, 
which is characterized by 
the proliferation of mature, 
antibody-secreting plasma 
B cells in the bone marrow. 
Notable characteristics of 
MM include the contribu-
tion of growth factors from 
stromal cells in the bone 
marrow microenviron-
ment to tumor cell survival 
and growth and an abun-
dance of chromosomal 
abnormalities in most MM 
cells. In spite of a variety 
of current MM therapies, 
clinical outcome is often 
poor, variable, and unpre-
dictable. As such, much 
effort has recently been 
devoted to using genetic 
and gene expression micro-
array approaches to define 
MM molecular subtypes 
and how molecular sub-
types might be used to 
direct and predict suscep-
tibility to various treatment 
regimens (Carrasco et al., 2006; 
Shaughnessy et al., 2007; Mulligan 
et al., 2007).
NF-κB defines a family of transcrip-
tion factor dimers (made up of combi-
nations of p50, p52, c-Rel, p65/RelA, 
and RelB); such dimers are inac-
tive in the cytoplasm in most normal 
cells, due to the interaction of NF-
κB dimers with IκB inhibitors. Many 
extracellular signals, usually acting 
through membrane-bound receptors 
and a series of adaptor and modula-
tor proteins, activate NF-κB, that is, 
induce the nuclear translocation of 
NF-κB as a consequence of protea-
some-mediated degradation of IκB. 
Proteasome-mediated degradation 
of IκB is promoted by stimulus-pro-
voked phosphorylation of IκB by an 
IκB kinase (IKK) complex. Two major 
pathways lead to activation of NF-κB: 
a classical (or canonical) pathway and 
an alternative (or noncanonical) path-
way (Figure 1). These two 
pathways, however, show 
much interplay and overlap: 
many signals activate both 
NF-κB pathways, many 
of the same cytoplasmic 
effector proteins (adaptors, 
kinases) are used in both 
pathways, and many target 
genes are activated by both 
pathways. For the most 
part, the classical pathway 
is defined by activation of 
p50-p65 complexes upon 
degradation of an associ-
ated IκB, and the alterna-
tive pathway is character-
ized by processing of an 
inactive p100-RelB dimer 
to active p52-RelB through 
degradation of C-terminal 
IκB-like sequences of NF-
κB2 p100 (the precursor to 
p52). Both NF-κB pathways 
can be effectively blocked 
by proteasome inhibitors, 
which interrupt NF-κB sig-
naling by inhibiting degra-
dation of IκB proteins.
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Multiple myeloma (MM) is a late-stage B cell malignancy that has received much attention recently 
because of its therapeutic susceptibility to proteasome inhibitors. Two papers in this issue of Cancer 
Cell show that primary MM samples and MM cell lines frequently have mutations in genes encoding 
regulators and effectors of NF-κB signaling, and that these mutations lead to chronic NF-κB target 
gene expression, which is required for the viability of these MM tumor cells. These results reveal the 
molecular basis for constitutive NF-κB activity in many MMs and further validate the NF-κB signaling 
pathway as an appropriate target for MM therapy.
Figure 1. NF-κB Signaling Pathway Mutations in Multiple 
Myeloma
Shown are the classical and alternative NF-κB signal transduction 
pathways that lead to activation of nuclear NF-κB DNA binding and 
target gene expression. Arrows indicate activating steps; bars indicate 
inhibitory steps. Negative regulators of NF-κB signaling that undergo 
loss-of-function mutations in MM are designated in red font. Positive 
regulators and effectors of NF-κB signaling that undergo gain-of-func-
tion mutations in MM are in blue font. In both cases, these mutations 
lead to constitutive nuclear NF-κB activity and increased target gene 
expression in MM. BTZMB (bortezomib; proteasome inhibitor) and 
MLN (MLN120b; IKKβ inhibitor) are small molecules that inhibit both 
NF-κB signaling and MM cell growth. See text for further details.Cancer Cell 12, August 2007 ©2007 Elsevier Inc. 95
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PreviewsSeveral studies have shown that 
many MM cell lines have constitu-
tively nuclear NF-κB activity and that 
such NF-κB-positive MM cell lines 
are sensitive to growth inhibition by 
blockers of NF-κB signaling (e.g., 
Hideshima et al., 2006; Jourdan et 
al., 2007)). Indeed, the proteasome 
inhibitor bortezomib has shown con-
siderable clinical efficacy toward 
MM, which is likely due in large part 
to bortezomib’s anti-NF-κB signal-
ing activity (Richardson et al., 2007). 
However, the molecular basis for 
constitutive NF-κB activity in MM 
was largely unknown, and as such, 
it was not known how one might 
predict sensitivity of MM patients to 
anti-NF-κB therapy. In two papers in 
this issue of Cancer Cell (Annunziata 
et al., 2007; Keats et al., 2007), it is 
shown that many MM cell lines and 
primary tumor cells have mutations 
in genes encoding positive and neg-
ative regulators of NF-κB signaling, 
and these mutations cause these 
MMs to have constitutive nuclear 
NF-κB activity, which is required for 
their survival.
The current papers use a variety 
of genomic (comparative genomic 
hybridization, direct gene sequenc-
ing) and gene expression studies 
(microarrays) to identify NF-κB-acti-
vating mutations in 15%–20% of 
several hundred MM cell lines and 
patient samples. It is noteworthy that 
extreme variations in individual RNA 
levels by microarray expression pro-
filing could be used to predict genetic 
aberrations: that is, extremely low 
mRNA expression could predict gene 
deletion/mutation, and high expres-
sion sometimes pointed to gene 
amplification or translocation.
Genes in MM that contained gain-
of-function mutations (such as ampli-
fications, translocations, point muta-
tions) for NF-κB signaling included 
ones encoding receptors known to 
activate NF-κB (CD40, LTβR, and 
TAC1), NIK (NF-κB-inducing kinase), 
NF-κB1 p50/p105, and NF-κB2 p52/
p100. For CD40, LTβR, and TAC1, 
receptor overexpression may be suf-
ficient to activate the NF-κB path-
way or might enhance the sensitivity 
of MM cells to factors in the tumor 96 Cancer Cell 12, August 2007 ©2007 Emicroenvironment. Overexpression 
of NIK or NF-κB1 p105 directly leads 
to constitutive activation of NF-κB. 
In the case of NFKB2, a deletion 
of sequences in the p100 IκB-like 
domain promotes processing of p100 
to p52 and activation of the alterna-
tive NF-κB pathway.
Mutations that induce chronic NF-
κB activation by loss of function (e.g., 
by deletions, point mutations, and/or 
loss of heterozygosity) occur in nega-
tive regulators of NF-κB signaling, 
including genes encoding TRAF2, 
TRAF3, cIAP1/2, and CYLD. In both 
studies, the most commonly found 
NF-κB-activating mutations in MM 
were ones that inactivated TRAF3. In 
some of the MM cell lines, inactivation 
of the TRAF and cIAP genes/proteins 
causes stabilization of NIK protein, 
which consequently should lead to 
chronic NF-κB activation. However, 
in some TRAF3-deficient MM cell 
lines, there may be NIK-independent 
pathways to NF-κB activation. CYLD 
is a deubiquitinating enzyme that 
negatively regulates NF-κB signaling 
at several levels.
Both types of mutations (gain and 
loss of function) were shown to cor-
relate with chronic activation of NF-
κB in MM, as judged by increased 
nuclear NF-κB DNA-binding activity 
and NF-κB target gene expression. 
It is likely that both the classical and 
alternative NF-κB pathways are acti-
vated by NF-κB pathway mutations 
in MM. However, given that TRAF2 
and TRAF3 are generally thought to 
be positive regulators of the classical 
NF-κB pathway, but negative regula-
tors of the alternative NF-κB pathway 
(Xia and Chen, 2005), and NIK activ-
ity is usually associated with activa-
tion of the alternative NF-κB pathway, 
the alternative NF-κB pathway may 
be more important for MM pathology. 
Nevertheless, it is clear that small-
molecule inhibitors of IKKβ (which 
is specific for the classical NF-κB 
pathway) can inhibit MM cell growth 
(Hideshima et al., 2006; Annunziata et 
al., 2007; Jourdan et al., 2007); more-
over, knockdown of IKKα (required for 
alternative NF-κB signaling in many 
systems) did not inhibit MM cells with 
activating mutations in NIK (Annunzi-lsevier Inc.ata et al., 2007). A possible explana-
tion for these paradoxes is that gross 
alteration in expression or activity of 
NF-κB regulatory molecules like NIK 
or TRAFs (as might occur by ampli-
fication or deletion) may lead to mis-
regulation of an NF-κB pathway that 
they do not ordinarily affect.
The importance of NF-κB-activat-
ing mutations for MM cell growth was 
shown in two ways: knockdown of 
NIK protein levels in MM cell lines with 
NIK amplification or re-expression of 
TRAF3 in TRAF3-deficient MM cell 
lines was toxic for cell growth/viabil-
ity. Although NF-κB-activating muta-
tions were identified in about 20% of 
MM cell lines/tumors, Annunziata 
et al. found that more than 60% of 
MM cell lines are sensitive to growth 
inhibition by a small-molecule inhibi-
tor of IKKβ. This result suggests 
either that many MM tumors have 
epigenetic means to activate NF-κB 
or that several other types of NF-κB-
activating mutations remain to be 
identified in MM samples. Indeed, 
a somatic tumor-specific mutation 
in RELA that alters p65’s DNA-bind-
ing activity was reported in one MM 
case (Trecca et al., 1997). It is inter-
esting that many genes encoding 
regulators and effectors of the NF-
κB pathway are themselves NF-κB 
target genes, providing a possible 
feed-forward mechanism for sus-
taining NF-κB activity.
These two studies also showed 
that normal plasma B cells and cells 
from the pre-MM state (monoclonal 
gammopathy of undetermined signifi-
cance [MGUS]) have high expression 
of the same NF-κB target genes seen 
in MM. In normal plasma B cells, the 
NF-κB activity is induced by growth 
factors produced in the bone mar-
row microenvironment. Thus, these 
studies suggest that one step in 
MM development is the progression 
from a microenvironment-dependent 
NF-κB-activated state to an NF-
κB-activated state with reduced or 
abolished dependence on the micro-
environment, such as can occur by 
some of the described NF-κB-acti-
vating mutations. It is not clear how 
other common genetic alterations in 
MM, such as FGFR3 translocation or 
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PreviewsCYCLIND dysregulation (an NF-κB 
target gene), correlate or cooperate 
with genetic activation of NF-κB.
By using NF-κB target gene 
expression profiles to identify MM 
patients likely to have TRAF3 dele-
tions among cohorts of patients 
treated with dexamethasone versus 
bortezomib, Keats et al. found that 
only 2/20 patients with TRAF3 inacti-
vation responded to dexamethasone, 
whereas 17/19 patients among the 
TRAF3 inactivation group responded 
to bortezomib. These results sug-
gest that constitutive activation of 
the NF-κB pathway through TRAF3 
inactivation is correlated with dexa-
methosone resistance and bortezo-
mib sensitivity. Although the exact 
molecular basis for the differential 
sensitivity of individual MM patients 
to bortezomib versus dexamethasone 
is not clear, it appears that TRAF3 
status, which can be assessed fairly 
simply by conventional molecular 
techniques, should dictate treatment 
with proteasome inhibitors.As any poet or philosopher can tell 
us, it is in the contemplation of death 
that we gain insight into life. Indeed, it 
was in their seminal The Meaning of 
Life, Death, BH3 
and the Salmon M
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New drugs that neutralize the ant
cancer therapies, both alone an
and why such agents may trigg
can occur, depends on the comp
outer membrane permeabilizatio
exposing them to peptides corre
not only which cells will undergo
cells may be resistant.These two studies add to the 
growing body of evidence demon-
strating that mutations in NF-κB 
pathway genes are rather common 
occurrences in a variety of malig-
nancies (Courtois and Gilmore, 
2006). Why certain NF-κB-activat-
ing gene mutations appear to occur 
only in some types of tumors is 
not clear. Nevertheless, the current 
studies take us one step closer to 
understanding the molecular under-
pinnings of MM and toward design-
ing and designating more effective 
therapies for individuals with MM.
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